[Development in the immunotherapy of malignant melanoma].
Recent progress in the investigation of malignant melanoma has encouraged the possibilities of using immunological methods in the treatment of cancer. Under investigation are especially attempts to influence both the humoral and cellular immunity with cytotoxic effect on tumor cells. In perspective of these studies schedules for greater effectiveness of immunotherapy by combination of active, passive, eliminative or adoptive methods are conceivable. They provide a rational basis particulary because essential questions of alternation between the immune reactions are not yet understood.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D004137:Dinitrochlorobenzene / Q000627:therapeutic use; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009362:Neoplasm Metastasis; D012900:Smallpox Vaccine / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000502:physiology; D014165:Transfer Factor
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D004137:Dinitrochlorobenzene; D012900:Smallpox Vaccine; D014165:Transfer Factor
Ubersichten. Entwicklungen in der Immuntherapie des malignen Melanoms.